A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy Alone Versus Neoadjuvant Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post- Surgery Therapy With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle- Invasive Bladder Cancer
Sponsor: Bristol-Myers Squibb
This observational or N/A phase trial investigates Muscle-Invasive Bladder Cancer and Urinary Bladder Neoplasms and is currently ongoing. Bristol-Myers Squibb leads this study, which shows 40 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
40 versions recorded-
Apr 17, 2026 — Present [daily]
Active Not Recruiting
-
Apr 16, 2026 — Apr 17, 2026 [daily]
Active Not Recruiting
Phase: PHASE3 → None
-
Feb 2026 — Apr 2026 [monthly]
Active Not Recruiting PHASE3
-
Sep 2025 — Feb 2026 [monthly]
Active Not Recruiting PHASE3
-
Jun 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
▶ Show 35 earlier versions
-
Sep 2024 — Jun 2025 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Feb 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
-
Feb 2023 — Feb 2024 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Dec 2022 — Feb 2023 [monthly]
Recruiting PHASE3
-
Jul 2022 — Dec 2022 [monthly]
Recruiting PHASE3
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE3
-
Apr 2022 — Jun 2022 [monthly]
Recruiting PHASE3
-
Feb 2022 — Apr 2022 [monthly]
Recruiting PHASE3
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE3
-
Sep 2021 — Jan 2022 [monthly]
Recruiting PHASE3
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Oct 2020 — Nov 2020 [monthly]
Recruiting PHASE3
-
Sep 2020 — Oct 2020 [monthly]
Recruiting PHASE3
-
Aug 2020 — Sep 2020 [monthly]
Recruiting PHASE3
-
Jul 2020 — Aug 2020 [monthly]
Recruiting PHASE3
-
Jun 2020 — Jul 2020 [monthly]
Recruiting PHASE3
-
May 2020 — Jun 2020 [monthly]
Recruiting PHASE3
-
Apr 2020 — May 2020 [monthly]
Recruiting PHASE3
-
Mar 2020 — Apr 2020 [monthly]
Recruiting PHASE3
-
Feb 2020 — Mar 2020 [monthly]
Recruiting PHASE3
-
Jan 2020 — Feb 2020 [monthly]
Recruiting PHASE3
-
Dec 2019 — Jan 2020 [monthly]
Recruiting PHASE3
-
Nov 2019 — Dec 2019 [monthly]
Recruiting PHASE3
-
Oct 2019 — Nov 2019 [monthly]
Recruiting PHASE3
-
Sep 2019 — Oct 2019 [monthly]
Recruiting PHASE3
-
Aug 2019 — Sep 2019 [monthly]
Recruiting PHASE3
-
Jul 2019 — Aug 2019 [monthly]
Recruiting PHASE3
-
Jun 2019 — Jul 2019 [monthly]
Recruiting PHASE3
-
May 2019 — Jun 2019 [monthly]
Recruiting PHASE3
-
Apr 2019 — May 2019 [monthly]
Recruiting PHASE3
-
Dec 2018 — Apr 2019 [monthly]
Recruiting PHASE3
-
Nov 2018 — Dec 2018 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Oct 2018 — Nov 2018 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
The purpose of this study is to compare nivolumab plus neoadjuvant gemcitabine/cisplatin (GC) chemotherapy, followed by post-surgery continuation of immuno-oncology (IO) therapy, with neoadjuvant GC chemotherapy alone in adult participants with previously untreated muscle-invasive bladder cancer (MIBC).
Contact Information
- Bristol-Myers Squibb
- Ono Pharmaceutical Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aachen, Germany , Albany, United States , Amiens, France , Amsterdam, Netherlands , Angers, France , Athens, Greece , Atlanta, United States , Auckland, New Zealand , Austin, United States , Bari, Italy and 162 more locations